📊 ROIV Key Takeaways
Is Roivant Sciences Ltd. (ROIV) a Good Investment?
Roivant Sciences faces severe operational distress with collapsing revenue (-71.6% YoY) and unsustainable cash burn of $750M annually against only $8.3M revenue. Despite a strong balance sheet providing temporary runway, the company's massive operating losses and negative profitability across all metrics indicate fundamental business model failure requiring immediate strategic restructuring or asset liquidation.
Fundamentals show minimal revenue with extremely large operating and free cash flow losses, indicating no path to near-term profitability. While liquidity is exceptionally strong and leverage is low, negative revenue growth and inability to cover interest from operations make the risk/reward unattractive on fundamentals alone.
Why Buy Roivant Sciences Ltd. Stock? ROIV Key Strengths
- Strong balance sheet with $5.7B total assets and $4.5B stockholders equity provides short-term financial cushion
- Adequate liquidity with $1.4B cash reserves and exceptional current ratio of 18.37x eliminates immediate solvency risk
- Minimal financial leverage at 0.07x debt-to-equity ratio reduces leverage risk despite operational challenges
- Exceptional liquidity (current/quick >30x) and $1.48B cash
- Low leverage (0.07x D/E) with substantial equity base
- Capex-light model and YoY improvement in net loss
ROIV Stock Risks: Roivant Sciences Ltd. Investment Risks
- Severe revenue collapse of 71.6% YoY to $8.3M indicates fundamental business deterioration or major product/partnership failure
- Unsustainable cash burn of $750M annually against $1.4B reserves provides less than 2 years of operational runway without revenue inflection
- Massive operating losses of $515M on minimal revenue demonstrates inability to support current cost structure; operating margin of -6235.7% is untenable
- Sustained large operating losses and deeply negative FCF
- Tiny, declining revenue base with poor operating leverage
- Negative interest coverage and elevated dilution/financing risk
Key Metrics to Watch
- Quarterly revenue trend stabilization and growth trajectory
- Operating cash burn rate reduction and path to cash flow breakeven
- Clinical pipeline progress and regulatory approval milestones
- Quarterly operating cash burn vs cash runway
- Revenue growth from partnerships/licensing
Roivant Sciences Ltd. (ROIV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 18.37x current ratio provides a solid financial cushion.
ROIV Profit Margin, ROE & Profitability Analysis
ROIV vs Healthcare Sector: How Roivant Sciences Ltd. Compares
How Roivant Sciences Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Roivant Sciences Ltd. Stock Overvalued? ROIV Valuation Analysis 2026
Based on fundamental analysis, Roivant Sciences Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Roivant Sciences Ltd. Balance Sheet: ROIV Debt, Cash & Liquidity
ROIV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Roivant Sciences Ltd.'s revenue has declined by 41% over the 5-year period, indicating business contraction. The most recent EPS of $5.23 reflects profitable operations.
ROIV Revenue Growth, EPS Growth & YoY Performance
ROIV Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.0M | $34.5M | $0.05 |
| Q2 2025 | $1.6M | -$113.5M | $-0.17 |
| Q1 2025 | $2.2M | $95.3M | $0.12 |
| Q3 2024 | $9.0M | $34.5M | $0.05 |
| Q2 2024 | $3.6M | -$134.9M | $-0.18 |
| Q1 2024 | $21.6M | $95.3M | $0.12 |
| Q3 2023 | $17.1M | -$352.0M | $-0.49 |
| Q2 2023 | $12.5M | -$291.6M | $-0.40 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Roivant Sciences Ltd. Dividends, Buybacks & Capital Allocation
ROIV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Roivant Sciences Ltd. (CIK: 0001635088)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ROIV
What is the AI rating for ROIV?
Roivant Sciences Ltd. (ROIV) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 81% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ROIV's key strengths?
Claude: Strong balance sheet with $5.7B total assets and $4.5B stockholders equity provides short-term financial cushion. Adequate liquidity with $1.4B cash reserves and exceptional current ratio of 18.37x eliminates immediate solvency risk. ChatGPT: Exceptional liquidity (current/quick >30x) and $1.48B cash. Low leverage (0.07x D/E) with substantial equity base.
What are the risks of investing in ROIV?
Claude: Severe revenue collapse of 71.6% YoY to $8.3M indicates fundamental business deterioration or major product/partnership failure. Unsustainable cash burn of $750M annually against $1.4B reserves provides less than 2 years of operational runway without revenue inflection. ChatGPT: Sustained large operating losses and deeply negative FCF. Tiny, declining revenue base with poor operating leverage.
What is ROIV's revenue and growth?
Roivant Sciences Ltd. reported revenue of $8.3M.
Does ROIV pay dividends?
Roivant Sciences Ltd. does not currently pay dividends.
Where can I find ROIV SEC filings?
Official SEC filings for Roivant Sciences Ltd. (CIK: 0001635088) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ROIV's EPS?
Roivant Sciences Ltd. has a diluted EPS of $-0.54.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ROIV a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Roivant Sciences Ltd. has a SELL rating with 81% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ROIV stock overvalued or undervalued?
Valuation metrics for ROIV: ROE of -6.6% (sector avg: 15%), net margin of -3,629.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ROIV stock in 2026?
Our dual AI analysis gives Roivant Sciences Ltd. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ROIV's free cash flow?
Roivant Sciences Ltd.'s operating cash flow is $-750.3M, with capital expenditures of $8.2M. FCF margin is -9,183.5%.
How does ROIV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,629.2% (avg: 12%), ROE -6.6% (avg: 15%), current ratio 18.37 (avg: 2).